LGVN - Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ | Benzinga
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. The company just reported positive top-line results from its phase 2a trial of Lomecel-B™, its investigational product, for the treatment of mild Alzheimer’s disease.
In the trial of 48 patients ages 60 to 85 years old with mild Alzheimer’s disease, Lomecel-B™ met its primary safety endpoint and also showed statistically significant evidence of slowing disease progression as compared to placebo.
"We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, Chief Executive Officer of Longeveron, said when announcing the phase 2a trial results. "We look forward to announcing additional biomarker data from this trial which may further characterize the clinical effects of Lomecel-B™ in this study population.”
Targeting Neurodegeneration And Inflammation
Lomecel-B™ is made from medical signaling cells (MSCs) derived from the bone marrow of young, healthy adult donors. It is believed that MSCs travel to sites of damage or inflammation in the body and may promote cellular regeneration.
The promising results of its phase 2a trial come as the world reaches an inflection point with Alzheimer’s disease. About 6.7 million people ages 65 and older in the U.S. suffer from the disease. It’s only expected to get worse as the population continues to age. By 2060, it has been projected that Alzheimer’s disease may affect 14 million people in the U.S.
Lomecel-B™’s Potential For Other Conditions?
That’s not the only opportunity for Longeveron and Lomecel-B™. The experimental therapeutic treatment is also in phase 2 trials to treat Hypoplastic Left Heart Syndrome (HLHS) and Aging-related Frailty.
HLHS is a rare congenital heart defect in which the left side of the heart fails to develop, leading to short-term mortality, delayed development and long-term organ failure. HLHS affects about 1,000 babies in the U.S. annually and requires a three-stage open-heart surgery to survive, and even with the surgeries, early mortality and need for heart transplantation are still extremely high due to right ventricle failure. As a result, there is an important unmet medical need to improve right ventricular function in ...
LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™>Full story available on Benzinga.com